Two major pharmaceutical companies developing advanced-stage R&D on Alzheimer’s disease have just pulled the plug ontheir research. The reason why their approach to Alzheimer’s, Aducanumab, failed is because it didn’t account for a factor that is central to R&D conducted by biotechnology Company ProMIS Neurosciences Inc. (TSX:PMN, OTCQB:ARFXF, Forum).
Preclinical studies show the Company's lead antibody candidate, PMN310, demonstrates a high degree of binding to toxic oligomers from Alzheimer's disease brains without binding to plaque or other non-toxic forms of amyloid beta (Aß). Not only has an important competitor dropped out of the race to find an Alzheimer’s treatment, the reason for failure suggests that ProMis is on the right track with its own research.
(Image via ProMIS Neurosceinces.)
Stockhouse is joined by Company President and CEO, Dr. Elliot Goldstein to learn more about ProMIS’ research and potential to combat Alzheimer’s Disease.
FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.